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Abstract: Prenatal diagnosis of β-
by globin chain synthesis analysis on fetal blood obtained by placental aspiration at 18
weeks  gestation.  Since  then,  the  molecular  definition  of  the 
development  of  procedures  of  DNA  analysis,  and  the  introduction  of  chorionic  villous 
sampling  have  dramatically  improved  prenatal  diagnosis  of  this
disorders.  Much  information  is  now
diseases and the molecular testing is widespread. As prenatal diagnosis has to provide an 
accurate, safe and early result, an efficient screening of the population and a rapid molecular 
characterization of the couple at risk, are necessary prerequisites. In the l
and less invasive approaches for prenatal diagnosis were developed . A overview of the most 
promising procedure will be done. Moreover, in order to reduce the choice of
the  pregnancy  in  case  of  affected  fetus,  Preimplan
Diagnosis (PGD) has been setting up for several diseases including thalassemias
Introduction:  β-thalassemias  and  hemo
globinopaties are among the commonest autosomal 
recessive  diseases  with  a  high  frequency  in 
population  of  the  Mediterranean  area,  the  Middle 
East, the Indian subcontinent, the Far East, Tropical 
Africa  and  the  Caribbean.
1 However,  in  the  last 
decades, the steady migratory flows have rendered 
these  pathologies  much  more  widespread,  thus 
representing a general public health problem. In the 
‘70s the set-up of  globin chain  synthesis analysis 
for the detection of little amount of β-chains in fetal 
blood  during  the  18th-22th  week  gestation
allowed the development of screening programs of 
the general population, based on the identification 
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-thalassemia was accomplished for the first time in the 1970s 
by globin chain synthesis analysis on fetal blood obtained by placental aspiration at 18
weeks  gestation.  Since  then,  the  molecular  definition  of  the  β-globin  gene  pathology,  the 
ment  of  procedures  of  DNA  analysis,  and  the  introduction  of  chorionic  villous 
sampling  have  dramatically  improved  prenatal  diagnosis  of  this disease  and  of  related 
Much  information  is  now available  about  the  molecular  mechanisms  of  the 
s and the molecular testing is widespread.  As prenatal diagnosis has to provide an 
accurate, safe and early result, an efficient screening of the population and a rapid molecular 
characterization of the couple at risk, are necessary prerequisites. In the last decades
and less invasive approaches for prenatal diagnosis were developed . A overview of the most 
promising procedure will be done. Moreover, in order to reduce the choice of
the  pregnancy  in  case  of  affected  fetus,  Preimplantation  or  Preconceptional  Genetic 
Diagnosis (PGD) has been setting up for several diseases including thalassemias
thalassemias  and  hemo-
are among the commonest autosomal 
recessive  diseases  with  a  high  frequency  in 
population  of  the  Mediterranean  area, the  Middle 
East, the Indian subcontinent, the Far East, Tropical 
However,  in  the  last 
ory flows have rendered 
these  pathologies  much  more  widespread,  thus 
representing a general public health problem. In the 
up of  globin chain  synthesis  analysis 
chains in fetal 
week  gestation
2 has 
allowed the development of screening programs of 
the general population, based on the identification 
of the couple at risk, and, in addition, the offer of 
prenatal  diagnosis  testing.  At  that  time  the 
thalassemic patients  had  limited  lifespan  and 
prenatal diagnosis  represented  the only option for 
the  control  of  the  disease.  Such  programs  first 
started  in  Sardinia,  Continental  Italy,  Cyprus  e 
Greece.
3,4,5,6
Prenatal  diagnosis  on  fetal  blood,  even  if 
represented  for couple  at-risk  an  opportunity  to 
generate healthy sons, was not easily accepted. The 
late  gestational  age  in  which  fetal  diagnosis  was 
carried out, the risk of misdiagnosis due to  a not 
clear  cut-off    between  some  heterozygotes  and 
affected fetuses, the high risk of miscarriage due to 
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of the couple at risk, and, in addition, the offer of 
prenatal  diagnosis  testing.  At  that  time  the 
patients  had  limited  lifespan  and 
prenatal diagnosis  represented  the only option for 
the  control  of  the  disease.  Such  programs  first 
started  in  Sardinia,  Continental  Italy,  Cyprus  e 
Prenatal  diagnosis  on  fetal  blood,  even  if 
risk  an  opportunity  to 
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the  sampling  procedures,  made  indeed  the 
procedure difficult to accept from the couples. 
The continuous advances in the knowledge of 
the  molecular  pathology  of  the  disease,  the 
discovery  of  restriction  fragment  length 
polymorphisms (RFLP) linked to the β-like globin 
gene,  the  development  of  methodologies  for 
mutation  detection  and  the  application  of  the 
villocentesis  for  the  recovery  of  nucleated  fetal 
cells, allowed a fast improvement both in feasibility 
and acceptability of prenatal diagnosis. For a short 
period, in the eighties, the diagnosis of thalassaemia 
was obtained either indirectly  by linkage analysis 
using RFLP at the β-globin gene cluster
7 or directly 
by  oligonucleotide  hybridisation  on  electro-
phoretically  separated  DNA  fragments
8 or  by 
enzymatic  digestion  of  mutated  sites.  A  major 
impulse has been given by the PCR technology that 
allowed  the  development  of  a  number  of 
procedures, for easier mutation detection, as well as 
the  development  of  both  PGD  and  non  invasive 
prenatal  diagnosis  procedures.  Nowadays 
thalassaemias are detected directly by the analysis 
of amplified DNA from fetal trophoblast or, more 
rarely, from amniotic fluid cells. 
In  this  review  we  will  delineate  current 
procedures  for  prenatal  and  preimplantation 
diagnosis  of  thalassemias  as  well  as  the  most 
promising  approaches  for  non-invasive  prenatal 
diagnosis.
Prenatal Diagnosis
Detection Methods: Definition of molecular defect 
in  both  parents  is  a  prerequisite  for  prenatal 
diagnosis of the disease.
The majority of defects affecting the β-globin 
gene are point mutations that occur in critical areas 
for its function, or single/few base addition/deletion 
that  change  the  frame  in  which  triplets  are 
translated  into  protein.  Very  rarely  β-thalassemia 
results  from  gross  rearrangement  in  the  β-globin 
gene  cluster.  In  spite  of  the  marked  molecular 
heterogeneity,  a  limited  number  of  molecular 
defects  are  prevalent  in  every  at  risk  population. 
This may be very useful in practice, because a panel 
of most frequent mutations to be searched for can 
be designed according to the carrier's ethnic origin.
9
Known mutation detection is carried out by a 
number of PCR-based techniques. Among them, the 
most  commonly  used  are  the  primer-specific 
amplification  (ARMS,  Amplification  Refractory 
Mutation System)  and the  reverse  oligonucleotide 
hybridisation  with  specific  oligonucleotide  probes 
(RDB, Reverese Oligonucleotide-probe analysis).
Primer-specific  Amplification: The  method  is 
based  on  the  principle  that  a  primer  carrying  a 
mismatch  in  its  3’  region  cannot  anneal  on  its 
template.  With  this  method,  the  target  DNA 
fragment is amplified in two separate PCR reactions 
using  a  common  primer  and  either  of  the  two 
following  primers:  one  complementary  to  the 
mutation to be detected (β-thalassemia primer) and 
one  complementary,  at  the  same  position,  to  the 
normal  DNA  (normal  primer).  Normal  DNA  is 
amplified  only by  the  normal  primer  while  DNA 
from homozygotes only by the β-thalassemia primer 
and DNA from heterozygotes by both primers. A 
different  sized  fragment  of  the  β-globin  gene  is 
simultaneously co-amplified as an internal control 
of the PCR reaction.
10 The method is very simple as 
it requires, for each mutation to be searched, only 
two  PCR  reactions  followed  by  agarose  gel 
electrophoresis.  A  further  improvement  of  the 
methodology can be obtained by multiplexing the 
primers for  more than one mutation. In good hands 
the method is very safe and particularly useful in 
fetal  DNA  analysis  to  search  for  mutations 
previously detected in the parents.
Reverse Oligonucleotide Hybridization: When the 
spectrum of mutations to be searched is complex, 
ARMS is not the most appropriate method. In this 
case  RDB  results  to  be  more  informative  and 
efficient. The method uses membrane-bound allele-
specific oligonucleotide probes that hybridize to the 
complementary  sequence  of  the  PCR  product
prepared using patient DNA as starting template.
11
In this format, multiple pairs of normal and mutant 
allele-specific oligonucleotides can be placed on a 
small strip of membrane. Hybridization with PCR-
amplified β-globin gene is able to detect, in a single 
procedure, any of the mutations screened. Up to 20-
30  mutations  have  indeed  been  screened  in  one 
single  step  and  several  commercial  kits  are 
available  to  detect  the  most  common  beta 
thalassemia mutations in Mediterranean population.
Other  Known  Mutation-detection  Procedures:
Several  other  methods  have  been  developed  to 
search  for  known  mutations,  i.e.  oligonucleotide 
ligation  assay,
12 restriction  enzyme  digestion  of 
PCR products,
13 however some of them have been 
abandoned  in  routine  diagnostics  as  they  are  less 
informative or more complex.
In recent years  a real time PCR assay has been 
successfully applied to both carriers screening and 
prenatal diagnosis.
14 This is a one-step method that 
is  based  on  the  use  of  fluorescent  hybridization Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
probes followed by a melting curve analysis. The 
method,  which  allows  the  simultaneous  multiple 
mutation  detection,  has  been  successfully  applied 
also to the detection of maternal contamination.  In 
spite of these advantages its use is still limited as it 
needs a dedicated apparatus as well as an accurate 
population-based design of detection probes.
Technically, we can realistically predict further 
simplification  and  fully  automation  of  the 
procedures  for  the  detection  of  the  β-thalassemia 
mutation in carrier screening and prenatal diagnosis. 
Nowadays  a  number  of  systems  for  molecular 
detection  of  the  β-thalassemia  mutations  is 
commercially available, which are not  completely 
automated and quite  expensive.  Among  them, the 
oligonucleotide  microchip based-assays have been 
proposed many times for the large-scale detection 
of  mutations  in  genetic  diseases,  including  β-
thalassaemia.
15 Given  the  alternative  features  of 
high throughput and automation, the DNA chip has 
the potential to become a valuable method in future 
applications of mutation detection in medicine. At 
the moment the technology, developed several years 
ago, is  not  jet  transferred  in  the  clinical  practice, 
due to the higher costs and to the lower analytical 
sensitivity and specificity.
Unknown  Mutations  Detection: When  carriers 
escape to the above mutation detection approaches, 
further  investigations  need  to  be  carried  out  by 
alternative methods which uncover the presence of 
unknown  mutations  by  scanning  the  whole  gene. 
Denaturing  gradient  gel  electrophoresis 
(DGGE),
16,17,18 denaturing  High  Pressure  liquid 
Chromatography  (dHPLC)  and  Single  Strand 
Conformation Polimorphism (SSCP)
19 are the most 
widely  used  in  the  last  years,  followed  by  direct 
sequencing  analysis
20 which  characterizes  the 
undefined  mutation  found  by  these  methods. 
Nowadays,  considering  the  small  size  of  the  β-
globin  gene  (1,8kb),  the  simplified  technologies 
available and  the reduced costs of analysis, direct 
sequencing,  based  on  cycle  sequencing  with 
fluorescent dye terminators and automated capillary
DNA sequencing technology, seems to be the faster 
and  most  useful  approach  to  detect  unknown 
thalassemia mutations.
If  a  mutation  is  not  detected  by  sequence 
analysis,  we  search  for  the  presence  of  small 
deletions by polyacrylamide gel electrophoresis of 
amplicons  designed  for  the  most  frequent  small 
deletional defects of the β-globin gene (gap PCR). 
Furthermore, the presence of  larger deletions of the 
cluster  may  be  identified  by  Southern-blotting  or 
more  recently  by  Multiple  Ligation-dependent 
Probe  Amplification  (MLPA)  for  which  a 
commercial  kit  is  available  (SALSA  MLPA  KIT 
P102 HBB-MRC Holland).
In  a  very  limited  number  of  cases,  direct 
sequencing from position -600 to 60 bp downstream 
from  the  β-globin  gene  and  methods  for  deletion 
detection, failed to detect the disease causing defect. 
In  these  cases,  the  molecular  defect  may  reside 
either  in  the  locus  control  region  of  the  β-globin 
gene cluster, or in one of the genes, outside the β-
globin gene region, encoding for regulatory proteins 
acting in trans on the function of the β-globin gene. 
Very  recently  it  has  been  proved  that  the  β-
thalassaemia like phenotype could be caused by the 
coinheritance  of  a  β-globin  gene  defect  and  a 
duplication  of  the  α- globin  gene  cluster,  which 
results in  an  excess of  α  chain.  In  these  selected 
cases,  the  characterization  of  these  α-globin  gene 
rearrangements  (SALSA  MLPA  KIT  P140-B2 
HBA-MRC  Holland)  can  be routinely  carried out 
with success by MLPA analysis. 
Genetic Counseling  of  the Couple at Risk: Both 
members of the couple at risk are counseled in a 
non  directive  way. The nature of  the disease, the 
implications of being carriers and the reproductive 
choices are analyzed, specifically those concerning 
birth control, including prenatal or preimplantation 
diagnosis  and  the possibility,  in  case  of  affected 
fetus HLA compatible, to not interrupt pregnancy  
As for fetal testing, detailed information is offered 
regarding  the  risk  of  fetal  mortality,  the  risk  of 
misdiagnosis, and the mortality and morbidity of an 
abortion in case of affected fetus. 
Fetal DNA Sampling: Fetal DNA for analysis can 
be  obtained  from  either  amniocytes  or  chorionic 
villi. At present the most widely used procedure is 
chorionic  villi  sampling,  because  of  the  clear 
advantage  of  being  carried  out  during  the  first 
trimester of pregnancy, generally at the 10th-12th 
week of gestation.
21, 22, 23 The risk of fetal mortality 
associated with both methods is in the order of 1-
2%. Chorionic villi may be obtained transcervically 
or  transabdominally,  the  last  being  most  widely 
used, mainly because it has a low infection rate and 
a  lower  incidence  of  amniotic  fluid  leakage. 
Moreover it is a simple procedure, largely preferred 
by pregnant women, that can be carried out also in 
late gestational age.
Samples  obtained  by  villocentesis  need  to  be 
accurately  dissected  under  inverted  microscope in 
order to remove maternal decidua, that represent the 
major cause of diagnostic error in prenatal diagnosis 
of monogenic diseases,Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
Fetal DNA Analysis: Fetal DNA is analysed using 
the same methods described above for the detection 
of  known  mutations  during  carrier  molecular 
screening. To limit the possibility of misdiagnosis, 
we  analyse  chorionic  villous  DNA  with  two 
different  procedures:  i.e.  RDB  hybridisation  and 
primer-specific  amplification  ,  using  distinct 
couples of primers.
Misdiagnosis  may  occur  for  several  reasons: 
failure  to  amplify  one  copy  of  the  target  DNA 
fragment,  mispaternity,  maternal  contamination, 
and sample  exchange.  Misdiagnosis  for  failure of 
DNA  amplification  is  obviously  limited  by  the 
double  approach  described  above.  To  avoid 
misdiagnosis due to maternal contamination as well 
as  mispaternity  and/or  sample  exchange,  a  fetal 
DNA microsatellite analysis is usually performed to 
verify the presence of one allele from each parent.
9
In our hands, by the above mentioned PCR-based 
procedures, no misdiagnoses have occurred in more 
than 5000 cases. 
Currently,  prenatal  diagnosis  is  a  widely 
applied  and  well  accepted  procedure.  Among  the 
patients screened we have found an acceptability of 
99,3%  for  early  prenatal  diagnosis  by  CVS.  This 
data,  if  compared  with  previously  utilized 
procedures  such  as  fetal  blood  sampling,  with  an 
acceptability  of  93,2%,  and  96,4%  by 
amniocentesis, demonstrates how the acceptance of 
the procedure depends on its precocity.
22
The  screening  program  in  the  Mediterranean 
countries  have  proven  to  be  very  successful  in 
reducing  the  number  of  thalassemia  patients.  In 
Sardinia, thalassemia major was present in 1 in 250 
births,  and  has  declined  to  1  in  4000  births 
(Figure1).  Other  countries  in  which  such 
thalassemia  programs  have  been  introduced  also 
show similar trends.
Preimplantation  and  Preconceptional  Genetic 
Diagnosis: The  progress  in  assisted  reproduction 
and molecular genetics techniques, particularly the 
advent of PCR that has made possible to analyze the 
genotype  of  a  single  cell,  has paved  the  way  for 
preimplantation genetic diagnosis (PGD).
24,25
This technique was introduced as an option for 
avoiding  the  decision  to  terminate  an  established 
pregnancy  diagnosed  as  affected  by  conventional 
approaches.
The  term  preimplantation  genetic  diagnosis 
describes  those  procedures  which  involve  the 
removal of one or more nuclei from ovocytes (polar 
bodies) or embryos (blastomeres of trophectoderm 
cells)  to  test  for  mutation  in  the  target  gene  or 
aneuploidy before transfer. 
PGD  requires  that  couples  at  risk  undergo in 
vitro fertilization (IVF) even if not infertile and for 
this  reason a multidisciplinary approach including 
an appropriate genetic counseling and the referral to 
both  a  fertility  clinic  and  to  a  high  specialized 
molecular genetics laboratory is mandatory. 
Counseling for couples considering PGD must 
include additional information regarding at least the 
risk  associated  with  IVF  procedures  and  with 
embryo  biopsy,  the  technical  limitations  of  DNA 
analysis,  including  the  risk  of  failure  of  the 
procedure as well as that of misdiagnosis, and the 
need  of  subsequent prenatal  diagnosis  to  confirm 
the  result.  Beyond  that,  the  possibility  that  no 
embryos may be transferred and the dispositions of 
embryos  not transferred have also to be seriously 
considered. 
Cell Biopsy: Preimplantation may be carried out by 
either  cleavage-stage  biopsy  of  1-2  blastomeres, 
from an eight-cell embryo three days after in vitro 
fertilization carried out by ICSI (Intracytoplasmatic 
Sperm Injection), or by the biopsy of polar bodies. 
For cleavage-stage biopsy the embryo is grown 
in vitro until it reaches a six-eight cell stage, which 
usually occurs on the third day after insemination. 
Polar bodies diagnosis, pioneered by Verlinsky and 
his group in ’90,
26 is based on the analysis of the
first polar body of unfertilized eggs,
27 and may lead 
to distinguish between unfertilised eggs that carry 
the defective gene and those without the defect. The 
successive  sampling  and  analysis  of  the  second 
polar  body that is extruded from the oocyte  after
fertilization and completion of the second meiotic 
division,  is  carried  out  in  order  to  avoid 
misdiagnosis due to the high rate of recombination 
that happens during the first meiosis. By fertilizing 
in  vitro  only  the  eggs  without  the  defect  and 
replacing  them  in  the  mother,  a  successful 
pregnancy  with  a  normal  fetus  can  be  obtained. 
Recently a preconceptional genetic diagnosis based 
on  the analysis of only the first polar body has been 
proposed for countries in which the use of PGD and 
manipulation  of  embryos  is  prohibited.
28 This 
approach  although  permitting  to  avoid  the 
manipulation,  cryopreservation  and/or  discard  of 
sovranumerary  and/or  affected  embryos,  shows 
several problems: the need to obtain more then 10-
12  oocytes,  the  increased  risk  of  diagnostic  error 
and the increase of the technical difficulties. 
Blastocyst biopsy, even if it has the advantage 
to provide a higher number of cells,, is at present 
more rarely used because of the difficulties of the 
embryos to reach this stage in IVF programs. Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
Figure 1. Fall in the birth rate of homozygous -thalassemia in Sardinia.
The cleavage-stage biopsy of blastomeres from 
a  eight-cell  embryo  is  the  most  frequently  used 
PGD procedure all over the world. 
Detection Methods: Methods for mutation detection 
in PGD are always based on multiple steps of PCR. 
Mutations are detected in PCR products by various 
methods that combine speed, analytical sensitivity 
and  specificity.  In  particular,  a  first  round  of 
multiplex PCR is performed to amplify both the β-
globin gene region including the mutation and one 
or more polymorphic loci. Secondly,  two separated 
nested PCR reactions are performed to amplify the 
two or more selected genomic regions. Finally, the 
polymorphic  alleles  are  directly  detected  by 
capillary electrophoresis of the amplified fragment, 
while the presence of β-globin gene mutations are 
identified  by  a  subsequent  minisequencing 
reaction.
29 This approach is  expressely designed to 
detect the presence of the β-globin gene mutations 
and to monitor, in the same sample, the presence of 
contamination as well as the eventual allele drop-
out that represent the most frequent causes of error 
in PGD. 
Quality  Control: For  both  techniques  a  prenatal 
diagnosis by villocentesis is recommended in order 
to avoid diagnostic errors.
Successful pregnancies following the transfer of 
human embryos in which the β-globin gene defect 
has been excluded, occur only in 20-25% of cases 
and the birth rate of a child is even lower. Due to 
the  low  birth  rate  most  women  have  to  undergo 
PGD several times in order to give birth to a healthy 
child.
30
Transfer  of  no  more  than  1-2  embryos  is 
strongly  recommended  in  order  to  avoid  multiple 
pregnancies.
31 Elective  Single  Embryo  Transfer 
(eSET) is in fact a well established procedure which 
has  demonstrated  to  ensure  a  better  prognosis  of 
IVF patients.
32
PD or PGD? Among clinical geneticists there have 
been much discussion about the main goal of PD. 
Some have argued that the main aim is to avoid the 
birth of an affected child. Others have emphasized 
the  reproductive  confidence  and  the  purpose  of 
informing  couple  at  risk  about  the  status  of  the 
fetus. Several studies indicate that if there is no PD 
option,  a  large  proportion  (up  to  50%)  of  the 
couples at high risk of an affected child refrain from 
pregnancy  despite  their  wish  to  reproduce.  When 
PD is possible many more at-risk couples dare to 
embark on a pregnancy.
Most  experts  consider  PGD  as  an  additional 
option for couples at risk and not as a replacement 
for  conventional  prenatal  diagnosis.  PGD  is  still 
considered  a  highly  specialized  experimental 
procedure with limited results, mainly dedicated to 
couples  against  abortion  for  ethical  and  religious 
reasons and to a small proportion of couples, who 
have  experienced  repeated  abortion,  that  ask  for 
referral for this procedure.Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
At  present  its  use  in  routine  monitoring  of 
pregnancies  at  risk  is  precluded  by  the  technical 
demand  for  these  procedures,  the  difficulty  in 
organizing the service, and the high costs.
Simplification  of  preimplantation  and 
preconception  genetic  diagnosis,  together  with  an 
increase in the pregnancy rate, may lead to a more 
extensive use of the procedure in the future.
Non  Invasive  Prenatal  Diagnosis  (NIPD): 
Analysis of Fetal Cells in Maternal Blood. In the 
sections below the most significant studies, which 
have been carried out in this field of research, are 
briefly summarized. The most relevant results have 
been grouped in three different sections, according 
to the different cell type in which they have been 
acquired. A separate section is dedicated to the the 
NIPD of β-thalassemia.
Trophoblasts: The  first  evidence  that  fetal  cells 
circulate in maternal peripheral blood dates back to 
1893 when George Schmorl observed the presence 
of placentally derived trophoblasts in the lungs of 
17 autopsied women affected by severe eclampsia.
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In 1959 Douglas
34 established that migration of 
trophoblasts is a normal process during pregnancy 
and  twenty  five  years  later,  Covone  et  al
35
demonstrated that these cells could be detected in 
healthy  pregnant  women  as  early  as  six  weeks 
gestation.  They  also  found  that  an  increased 
concentration  of  trophoblast  cells  were  frequently 
present in women affected by preeclampsia. Further 
studies  have  established  that  trophoblasts are 
entrapped  in  the  maternal  lungs  and  rapidly 
removed from the pulmonary circulation.
36
Trophoblast-specific cell-surface antigens have 
not yet been characterized and several experimental 
evidences  have  shown  that  the  H315,  initially 
described as the specific antigen for trophoblasts, is 
indeed adsorbed in maternal leucocytes.
37
These are some of the reasons why, in recent 
years, trophoblasts are no longer considered as the 
best target cells for non invasive prenatal diagnosis. 
Nevertheless,  this  line  of research  has  not  yet 
completely  abandoned  as  the  characterization  of 
trophoblast-specific  antigens  is  one  of  the 
objectives  of  the  SAFE  (Special  Non-Invasive 
Advances  in  Fetal  and  Neonatal  Evaluation) 
Network  (for  more  information  please  visit 
www.safenoe.org).
Lymphocyte: Fetal lymphocytes are the second cell 
type  which  have  been  extensively  studied  as 
possible source of fetal DNA. In 1969 Walknowska 
et al
38 detected for the first time 46,XY karyotype 
cells in maternal peripheral blood of women bearing 
male  fetuses.  Ten  years  later  Herzenberg  and 
collegues described the use of FACS (Fluorescent 
Activated  Cell  Sorting)  as  a  method  for  the 
enrichment  of  fetal  lymphocyte  expressing  the 
HLA-A2  paternal  antigen.
39 Detection  of  Y 
chromosome was then obtained in the enriched cells 
deposited  directly  onto  microscope  slides,  thus 
confirming their fetal origin.
Unfortunately  other  groups  have  failed  to 
replicate  these  results  with  success,  even  if 
cytogenetic analysis were carried out in fetal cells 
flow sorted on the basis of several HLA differences 
and by using monoclonal antibodies. 
In the same years further studies demonstrated 
that lymphocytes were not removed from maternal 
circulation after delivery. One of the earliest study 
who  provided  the  first  evidences  that  fetal 
lymphocytes persist in maternal circulation one year 
after  delivery  was  published  in  1974.
40 Several 
years later Bianchi et al described the presence of 
fetal progenitor cells 27 years after delivery.
41
For  these  reasons  also  lymphocytes,  as 
trophoblasts, became an unattractive candidate for 
non invasive prenatal diagnosis.
Erythroblasts: One of the main advantage to study 
fetal  erythroid  cells  is  that  they  are  nucleated, 
terminally  differentiated  short-lived  cells  and  for 
this  reason  they  do  not  persist  in  maternal 
circulation  for  long  time  after  delivery. 
Furthermore, first primitive erythroblasts appear in 
embryonic bloodstream around the four-five weeks 
gestations  so  they  can  be  detected  early  during 
gestation. 
Nevertheless,  their  isolation  from  maternal 
peripheral blood is still problematic because of their 
rarity and the lack of a fetal specific antibody.
In 1990 Bianchi
42 firstly described a method for 
fetal  nucleated  erythroid  cells  enrichment,  which 
was  based  on  the  combined  use  of  flow  sorting 
(FACS)  and  CD71  transferrin  receptor,  highly 
expressed  in  erythroid  cells.  Two  years  later 
Gänshirt-Ahlert  et al
43 obtained  similar results by 
using  a  newly  detection  system  called  MACS 
(Magnetic Cell Sorting) which is based on the use 
of antibodies labeled with magnetic beads.
Since then, both system have been extensively 
improved  and  used,  by  several  groups,  following 
different  approaches  which  can  consist  in  the 
positive  selection  of  CD71  and/or  glycophorin-A 
fetal cells and/or in the negative depletion of CD45 
maternal  cells. Usually,  in  both  cases,  a  previous 
density  (Ficoll  or  Histopaque)  gradient 
centrifugation  step  is  carried  out  to  remove  non 
nucleated  maternal  erythrocytes.  A  schematicMedit J Hemat Infect Dis 2009, 1(1), Open Journal System 
Figure  2.  In  the  present  workflow  is  resumed  one  of  the  commonly  used  strategies for 
peripheral blood. PBMC Peripheral Blood Mononuclear Cell
Magnetic Activated Cell Sorting.
workflow resuming one of  the strategies used for 
isolating  fetal  NRBCs  from  maternal  peripheral 
blood  is  represented  in  figure  2.  Finally  both 
MACS  and  FACS  sorted  cells  are  labeled  with 
fluorescent antibodies  which  recognize embryonic 
(ε,  ζ)  or  fetal  (γ)  hemoglobin  chains  and  are 
eventually  subjected  to  FISH  analysis  for 
chromosome Y detection. An example of positive 
labeling with the antibody for -globin coniugated 
with  FITC  is  shown  in  figure  3
characterization  can  be  eventually  carried  out  in 
positive  fluorescent  cells  isolated  by  laser 
microdissection. 
Even with the high progress made in last twenty 
years  in  this  field,  the  methods  for  erythroblasts 
enrichment are still limited as they mostly result in 
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Even with the high progress made in last twenty 
years  in  this  field,  the  methods  for  erythroblasts 
enrichment are still limited as they mostly result in 
the  recovery  of  fetal  samples  with  low  yield 
(FACS) and scarce purity (MACS), being varia
contaminated by maternal cells. 
For these reasons in recent years several studies 
have been addressed to the proteomic field with the 
attempt to characterize novel fetal erythroblast cell
specific surface markers. 
For  example,  bi-dimensional  electro
coupled  with  mass  spectrometry  has  allowed  the 
identification  of  22  proteins,  differentially 
expressed in  sickle  erythrocytes  in  comparison  to 
healthy erythrocytes, and the detection of proteins 
up- or  downregulated  in  fetal erythroid  cells  in 
comparison  to  their  adult  counterparts.  Some  of 
these results  have  been  published  as  a full
application  and  the  data  concerning  the  new
isolating  fetal  NRBCs  from  maternal 
Nucleated Red Blood Cell, MACS
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Figure 3. Erythroblasts enriched from maternal blood and stained with monoclonal antibody for -globin coniugated with FITC. 
Nuclei are counterstained with DAPI. 
antibodies  developed  against  these  new  targets 
expect to be validated in large samples of maternal 
blood.
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In addition, further developments in fetal cells 
recovery are  expected  to  be obtained  through  the 
application  of  micro-fluidic  rare-cell  capture 
technologies 
45 which are being developed to detect 
not only fetal but also cancer as well as other rare 
cells in biologic fluids. 
Analysis of fetal cells in maternal blood and Non 
Invasive  Prenatal  Diagnosis  (NIPD)  of  β 
Thalassemia: Despite  the  difficulties  encountered 
to find the best target cell and the best method for 
their  enrichment  and  isolation,  several  attempts 
have been made in last twenty years, to transfer the 
results  of  these  researches  into  clinical  practice. 
Unfortunately  the  lack  of  reproducibility  of 
experiments hardly makes the isolation of fetal cells 
from maternal blood  as  a first choice method for 
NIPD  of  monogenic disorders.  Below  the  most 
significative  results  obtained  in  NIPD  of  β-
thalassemia are briefly summarized.
The  first  example  of  non  invasive  prenatal 
diagnosis of haemoglobinopathies was described in 
1990 by Camaschella et al.
46 The genetic test was 
carried  out  in  three  selected  couples  where  the 
mother was carrier of β-thalassemia and the father 
of  the  Hb  Lepore-Boston  trait.  The 
absence/presence  of  the  paternal  trait  was 
successfully  detected  in  PCR  amplified  samples 
(DNA extracted from T-lymphocyte depleted cells) 
and autoradiography. In this case the “enriched fetal 
cell” samples were obtained by incubating Ficoll-
separated cells of the mother with the CD 3-specific 
MoAb Leu 4 and then separating the positive cells 
with  goat-anti-mouse  immunoglobulin  G  (1gG)-
coated immunomagnetic beads.
In  those  years  most  of  the  studies  were 
addressed  to  couples  carrying  different  mutations 
and  only  aimed  to  the  exclusion  of  the  paternal 
allele in the enriched fetal cells, as most of the times 
they were contaminated from maternal cells.
In  subsequent  years,  even  if  the  fetal  cells 
enrichment and selection methods have been greatly Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
improved,  other  NIP  diagnosis  have  been  carried 
out but with fluctuating results. Below are described 
three significative examples of NIPD realized, with 
different level of success, by using single or pooled 
erythroid cells. 
In 1996 the group of  Y.W.Kan
47 reported the 
successful identification of two fetal genotypes by 
using  fetal  nucleated  erythroid  cells  selected  by 
MACS,  anti-ζ  globin  immunostaining  and  then 
isolated  by  microscopy  and  cell  scraping.  The 
presence/absence of sickle cell and beta thalassemia 
mutations of both parents were finally detected by 
Reverse  Dot  Blot  in  PCR  amplified  samples 
constituted by pools of fetal dissected cells.
Few  years  later  the  group  of  Di  Naro
48
replicated  this  results  using  a  slightly  different 
procedure  for  erythroblast  enrichment  which  was 
carried  out  by  Percoll  and  Gastrografin  multiple 
gradient  centrifugation.  Mutation  detection  was 
then  obtained  by  automated  sequencing  of  single 
cells amplified by PCR. According to authors, even 
if  the  risk  of  allele  drop  out  is  higher  when 
amplifying single cells, however the possibility to 
study  several  individual,  instead  of  pooled,  cells 
guarantees an accurate diagnosis of the fetal DNA.
More  recently  the  group  of  Kolialexi
49 has 
hardly tried to replicate these results. In this study, 
NIPD was performed through magnetic cell sorting 
(MACS) and microdissection of single NRBCs with 
a  laser  micromanipulation  system.  Single-cell 
genotyping was achieved by nested real-time PCR 
for  genotyping  β-globin  gene  mutations;  a 
multiplexed minifingerprinting was used to confirm 
the origin of the isolated cells and to exclude their 
possible contamination.  A total  of 224 cells were 
isolated  but  only  half  of  them  were  successfully 
amplified.  In  the  majority  (n=80)  of  these  cells 
minifingerprinting was not informative because of 
allele dropout  or  homozigosity.  In  the rest  of  the 
samples, 22 cells resulted to be of fetal origin, 26 
maternal while 80 were non informative. 
Analysis of  Fetal DNA in Maternal Plasma and 
Non  Invasive  Prenatal  Diagnosis  (NIPD)  of  β 
Thalassemia: The  existence  of  cell-free  nucleic 
acids within the human plasma was firstly reported 
in 1948 by Mendel and Metais
50 which described 
their  presence  both  in  normal  subjects  and  in 
individuals  affected  by  various  diseases.  Some 
decades  later  other  studies  have  confirmed  the 
presence of circulating DNA as well as of RNA in 
several  pathological  conditions  (pancreatitis, 
inflammatory diseases, cancer, diabetes, etc).
51
In 1997 Lo et al discovered for the first time 
that  a  fetus  may  release  cell-free  fetal  DNA 
(cffDNA) into maternal plasma, thus providing an 
alternative  to  fetal  cells  for  noninvasive  prenatal 
diagnosis.
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In  recent  years  more  information  have  been 
acquired about the concentration, the origin and the 
characteristics  of  the  cell-free  fetal  DNA  and 
several procedures have been developed in order to 
use it in prenatal diagnosis.
The  cell  free  DNA  is  constantly  present  in 
peripheral  blood  of  non  pregnant  women  and  its 
concentration increases during pregnancy. The cell-
free  fetal  DNA  represent  the  3-5%  of  the  DNA 
present  in  maternal  plasma  from  which,  after 
delivery, it is rapidly cleared.
Recent  studies  carried  out  by  microfluidic 
digital  PCR  have  revealed  that  cffDNA  can  be 
present  at  even  higher  concentrations  which  can 
reach  up  to  10-20%  of  total  DNA  in  maternal 
plasma.
53 Nevertheless,  because  of  the  high 
background of maternal DNA, an enrichment step is 
needed to obtain highly purified fetal DNA samples 
suitable for non invasive prenatal diagnosis.
Size-fractionation  agarose  gel  electro-phoresis 
is  one  of  the  methods  developed  for  fetal  DNA 
enrichment  and  consists  in  the  isolation  of  short-
length DNA fragments (< 300 bp of length) which 
is the medium length of the cffDNA. This method 
coupled with the peptide-nucleic-acid clamp (PNA) 
PCR, which selectively suppresses the amplification 
of  maternal  alleles,  and  with  the  Allele-specific 
Real-Time  PCR  for  mutation  detection,  has  been
used with success by Li et al
54 to detect mutations 
of  paternal  origin  in  fetuses  at  risk  for  β-
thalassemia. 
More recently
55 the same group has described a 
new  procedure,  still  based  on  size  fractionation 
method,  but  coupled  with  MALDI-TOF  mass-
spectrometry, a medium-throughput platform which 
detect with high sensitivity the presence of known 
and  unknown  point  mutations.  In  this  case  no 
suppression of maternal allele was carried out and 
the  molecular  diagnosis  was  addressed  to  the 
exclusion  of  the  paternal  mutated  allele.  The 
analysis  by  MALDI-TOF  preceded  by  size 
fractionation  has  given  improved  results,  in 
comparison  to  the  absence  of  enrichment,  in  the 
detection  of  the  codon  39  β-thalassemia  paternal 
allele.
Nevertheless,  for  eventual  future  diagnostic 
application  the  protocol  needs  to  be  validated  in 
larger  sample,  even  if  the  high  cost  of  the 
instrumentation  required  makes  this  platform 
difficult to apply in routine diagnostics and the size Medit J Hemat Infect Dis 2009, 1(1), Open Journal System 
fractionation  is  considered  an  enrichment  method
more susceptible to maternal contamination.
The  use  of  peptide-nucleic-acid  clamping  to 
suppress  the  amplification  of  normal  maternal 
alleles  was  firstly  described  by  Cremonesi  in 
2004.
56 Peptide  nucleic  acid  are  artificially 
synthesized polymers  similar to nucleic acids and 
able to hybridize DNA sequences. The PNA/DNA 
hybrids are more stable than equivalent DNA/DNA 
hybrids but less stable in the presence of single-pair 
mismatches. In that paper their ability to clamp wild 
type  β-globin  sequences  was  proved  in  artificial 
mixture of  DNA samples enriched with increased 
amounts of wild type alleles, by using a microchip 
platform to detect the β-thalassemia mutations.
Four  years  later
56 the  efficacy  of  PNA  was 
evaluated with success in 41 non invasive prenatal 
diagnosis of β-thalassemia and in combination with 
three  different  techniques  (microelectronic  chip, 
pyrosequencing  and  direct  sequencing)  to  detect 
fetal DNA mutations in maternal plasma.
Despite  its  successfully  application,  this 
strategy, as the other above described technologies, 
is  still  restricted  to  couples  which  carry  different 
mutated  alleles  and  aimed  to  the  detection  of 
mutated paternal alleles. 
Another method recently described for NIPD of 
β-thalassemia  is  called  APEX  namely  Arrayed 
Primer  Extension.  This  is  a  mutation  detection 
system which is based on the combined use of the 
microchip  technology  and  the  single  nucleotide 
base  extension  method.  This  system  has  been 
recently described by the group of Papasavva
57 and 
used to characterize the presence of the paternal β-
thalassemia mutations and associated β-globin gene 
SNPs,  in  cffDNA isolated  from  maternal  plasma. 
The  possibility  to  study  the  polymorphisms 
associated to the mutated alleles represent a feature 
of great value since it would give the possibility to 
extend  NPID  to  couples  which  carry  the  same 
mutated allele. Prerequisite for its application is to 
find  informative  SNPs  associated  with  parental 
mutations  which  can  help  to  discriminate  the 
paternal  mutated  allele  and  to  characterize  the 
haplotypes inherited from the fetus. The authors of 
the paper described the correct application of this 
methodology  in  the  NIPD  of  six  out  of  seven 
couples at risk for β-thalassemia, carried out in the 
Cypriot population.
Future Perspective: As previously reported, one of 
the major problem which still limits the application 
of the described protocols in clinical practice is the 
impossibility to obtain highly purified fetal, cellular 
as well as cffDNA, samples which could allow the 
detection  of  parental  alleles,  even  when  they  are 
identical.  Few  clinical  applications  of  NIPD  are 
actually  restricted  to  the  detection  of  the  Y 
chromosome,  for  fetal  sex  determination,  or  the 
Rhesus D gene, in Rhesus D negative women, or, in 
general,  of  genetic  loci  which  are  absent  in  the 
maternal genome.
In recent years a great improvement has been 
obtained in the field of the technologies which can 
explore the presence of sequence variations even in 
single molecules of DNA. The concept of “Digital 
PCR” was firstly in introduced in 1992 by Sykes
58
who described a method to determine the number of 
starting DNA template by doing Poisson statistical 
analysis  of  PCR  results  obtained  in  limiting 
dilutions.  The  more  recent  development  of  the 
emulsion PCR (emPCR) have further enhanced the 
possibility  to  study  single  molecules  of  DNA  by 
using  small  volume  of  reactions,  water-oil 
emulsions  and  microfluidic  as  well  as  high-
throughput platforms (for a review of both methods 
and application to NIPD please see Zimmermann et 
al.
59
Recent applications of these technologies in the 
field of NIPD, and in particular in the diagnosis of 
aneuploidies and monogenic disorders, have shown 
that  these  methodologies  may  find  useful 
application  in  the  near  future,  even  if  several 
drawbacks  need  to  solved  and  wider  validation 
studied  should  be  carried  out  before  transferring 
their use in routine diagnostics.
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